GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now
GSK shares closed at $47.9 on November 28, just below a 52-week high, after a year-to-date gain of about 30–40%. The company beat earnings expectations in Q2 and Q3, raised full-year guidance, and saw its cancer drug Blenrep re-approved in major markets. CEO Emma Walmsley will step down December 31, with Luke Miels to take over January 1. Most analysts rate the stock a “Hold” despite recent outperformance.